Skip to main content
. 2018 Sep 4;10(10):e9155. doi: 10.15252/emmm.201809155

Figure 5. Treatment of iCCM2 and iCCM3 mice with indirubin‐3‐monoxime (IR3mo) alleviates the lesion burden within the cerebellum.

Figure 5

  • A–D
    Shown are representative pictures of brains at P8 from iCCM2 (A, B) or iCCM3 (C, D) mice treated with vehicle (A, C) or with IR3mo (B, D). Mice were treated daily between P2 and P7 with vehicle or with IR3mo. Scale bar is 1 mm.
  • E
    Treatment with IR3mo does not affect cerebellum width at P8 of iCCM2 mice. The measurements were performed on seven vehicle‐treated and eight IR3mo‐treated mice (n = 7, n = 8). Student's two‐tailed t‐tests were performed; error bars are SD. ns, not significant.
  • F
    Treatment with IR3mo does not affect animal weight at P8 of iCCM2 mice. The measurements were performed on eight vehicle‐treated and eight IR3mo‐treated mice (n = 8, n = 8). Student's two‐tailed t‐tests were performed; error bars are SD. ns, not significant.
  • G, H
    Quantifications of relative numbers of caverns within three categories based on cavern size. Cerebellar regions were measured in iCCM2 and iCCM3 mutants at P8 after treatment with vehicle (n = 8 for iCCM2 and n = 5 for iCCM3) or IR3mo (n = 8 for iCCM2 and n = 6 for iCCM3). Student's two‐tailed t‐tests were performed; error bars are SD. ns, not significant; *P < 0.05; **P < 0.01.
  • I
    Model scheme showing the molecular effect of IR3mo treatment on the ERK5 phosphorylation levels and the KLF2 expression levels in the CCM loss‐of‐function context. Two arrowheads indicate different molecular effects of IR3mo within the ERK5‐KLF2 pathway.